EyePoint, Inc. EYPT
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E technology (Durasert E) for sustained intraocular drug delivery. The Company's lead product candidate, DURAVYU1, is an investigational sustained delivery treatment for vascular endothelial growth factor (VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI) with the Company's bioerodible Durasert E drug delivery technology. DURAVYU is currently being evaluated in Phase 3 pivotal trials (LUGANO and LUCIA) for wet age-related macular degeneration (wet AMD) and in Phase 3 clinical trials (COMO and CAPRI) for diabetic macular edema (DME). Additional pipeline programs include EYP-2301, razuprotafib, a TIE-2 agonist, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EyePoint is headquartered in Watertown, Massachusetts with a commercial manufacturing facility in Northbridge, Massachusetts.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $31.4M | $43.3M | $46.0M | $41.4M | $36.9M | $34.4M | $20.4M | $3.0M | $7.5M | $1.6M |
| R&D | $221.0M | $132.9M | $64.7M | $49.6M | $28.5M | $17.4M | $15.4M | $16.2M | $14.9M | $14.4M |
| SG&A | $51.6M | $52.4M | $40.1M | $34.8M | $25.6M | $20.7M | $17.9M | $11.5M | $11.2M | $9.0M |
| Total operating expenses | $274.8M | $189.1M | $121.1M | $141.0M | $92.2M | $71.7M | $68.2M | $29.2M | $26.1M | $23.4M |
| Operating income | -$243.4M | -$145.9M | -$75.1M | -$99.6M | -$55.3M | -$37.3M | -$47.9M | -$26.3M | -$18.6M | -$21.8M |
| Interest expense | $33.0K | $14.0K | $1.2M | $3.2M | $5.5M | $7.3M | $6.2M | $720.0K | $0 | $0 |
| Pre-tax income | -$231.7M | -$130.8M | -$70.7M | -$102.3M | -$58.4M | -$45.4M | -$56.8M | -$53.2M | -$18.5M | -$21.7M |
| Income tax | $279.0K | $90.0K | $83.0K | $0 | $0 | $0 | $0 | $0 | $0 | $155.0K |
| Net income | -$232.0M | -$130.9M | -$70.8M | -$102.3M | -$58.4M | -$45.4M | -$56.8M | -$53.2M | -$18.5M | -$21.5M |
| EPS, basic | -3.17 | -2.32 | -1.82 | -2.74 | -2.03 | — | — | — | -0.52 | -0.68 |
| EPS, diluted | -3.17 | -2.32 | -1.82 | -2.74 | -2.03 | -3.54 | -5.44 | -1.15 | -0.52 | -0.68 |
| Shares, diluted (wtd. avg.) | $73.3K | $56.3K | $38.9K | $37.3M | $28.8M | — | — | — | $35.3M | $31.6M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $101.8M | $99.7M | $281.4M | $95.8M | $178.7M | $45.1M | $22.4M | $45.4M | $17.0M | $15.5M |
| Short-term investments | $204.3M | $271.2M | $49.8M | $48.9M | $33.0M | $0 | — | — | — | $13.7M |
| Inventory | $1.8M | $2.3M | $3.9M | $2.9M | $3.6M | $5.3M | $2.1M | $279.0K | $0 | — |
| Total current assets | $328.7M | $383.3M | $344.8M | $172.8M | $237.7M | $63.1M | $41.7M | $47.6M | $17.7M | $30.0M |
| Property, plant and equipment | $9.0M | $8.2M | $5.3M | $1.4M | $476.0K | $630.0K | $357.0K | $288.0K | $313.0K | $290.0K |
| Other intangibles | — | — | — | $0 | $22.7M | $25.2M | $27.7M | $30.1M | $364.0K | $1.1M |
| Total assets | $364.0M | $418.5M | $355.2M | $180.4M | $263.4M | $91.7M | $73.0M | $78.2M | $18.7M | $31.6M |
| Accounts payable | $10.5M | $11.7M | $6.5M | $5.9M | $7.4M | $4.8M | $4.2M | $2.6M | $1.0M | $1.4M |
| Short-term debt | — | — | $0 | $10.5M | $0 | — | — | — | — | — |
| Total current liabilities | $37.0M | $49.0M | $63.3M | $34.5M | $23.7M | $14.9M | $11.5M | $21.5M | $5.3M | $5.1M |
| Long-term debt | — | — | — | $29.3M | $36.6M | $38.0M | $47.2M | $17.6M | $0 | — |
| Total liabilities | $57.9M | $82.0M | $88.9M | $84.0M | $79.0M | $73.2M | $64.6M | $40.5M | $5.3M | $10.7M |
| Retained earnings | -$1.10B | -$873.0M | -$742.1M | -$671.4M | -$569.1M | -$510.7M | -$465.3M | -$408.5M | -$310.8M | -$292.2M |
| Total equity | $306.1M | $336.5M | $266.3M | $96.4M | $184.4M | $18.5M | $8.3M | $37.6M | $13.3M | $20.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$240.1M | -$126.2M | $1.9M | -$65.0M | -$50.1M | -$14.4M | -$56.7M | -$21.9M | -$20.5M | -$16.3M |
| Depreciation and amortisation | $2.3M | $1.5M | $464.0K | $396.0K | $311.0K | $189.0K | $144.0K | $167.0K | $91.0K | $152.0K |
| Stock-based compensation | $27.9M | $36.7M | $12.1M | $14.2M | $7.4M | $5.5M | $4.6M | $2.7M | $2.5M | $2.2M |
| Capital expenditure | $3.3M | $4.1M | $3.5M | $2.1M | $156.0K | $362.0K | $213.0K | $108.0K | $147.0K | $113.0K |
| Investing cash flow | $68.6M | -$219.4M | -$3.3M | -$17.3M | -$33.1M | -$362.0K | -$213.0K | -$16.9M | $13.6M | -$4.5M |
| Financing cash flow | $173.6M | $164.0M | $187.1M | -$690.0K | $216.9M | $37.5M | $33.9M | $60.7M | $8.5M | $17.0M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-182035.
Others in SIC 3826
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| A | AGILENT TECHNOLOGIES, INC. | $42.53B | 33.0x | 6.7% |
| WAT | WATERS CORP /DE/ | $40.22B | 38.0x | 7.0% |
| ILMN | ILLUMINA, INC. | $32.95B | 40.0x | -0.7% |
| MTD | METTLER TOLEDO INTERNATIONAL INC/ | $26.95B | 32.0x | 4.0% |
| RVTY | REVVITY, INC. | $14.53B | 62.9x | 3.7% |
| BIO | BIO-RAD LABORATORIES, INC. | $10.33B | 13.9x | 0.7% |
| AVTR | Avantor, Inc. | $10.22B | — | -3.4% |
| BRKR | BRUKER CORP | $8.88B | — | 2.1% |